Medical device to treat Benign Prostate Hyperplasia
All Portfolio items
See full Venture&Growth portfolio
Proverum is an Irish medical device company founded in 2016 as a spin-off from Trinity College Dublin. The company is developing a novel treatment solution for patients with symptomatic BPH designed to be safely and effectively performed in a doctor’s office setting in a simple procedure under local anaesthesia. Gilde invested in 2022 to support the Company’s clinical programme and other operating activities in pursuit of regulatory approval for the ProVee system in Europe and the US.
More Proverum news
Spanish Therapeutics company developing treatment of vascular calcification disorders of kidney patients.
UK-based digital therapy company focused on mental disorders.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate...